Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.

abstract：:Objective: To evaluate the efficacy of an intervention utilizing patient navigators (PNs) to 1) educate families on human papillomavirus (HPV) vaccination in a clinic setting and 2) provide personalized reminders for follow-up. Method: Families with 9-17 year-old children who had no record of completing the HPV vaccin...

journal_title：Human vaccines & immunotherapeutics

authors： Berenson AB,Rupp R,Dinehart EE,Cofie LE,Kuo YF,Hirth JM

更新日期：2019-01-01 00:00:00

abstract：BACKGROUND:Febrile seizure is the most common childhood neurological disorder, is an important health problem with potential short- and long-term complications, also leading to economic burden and increased parental anxiety about fevers and seizures occurring in their children. There are no routine recommendation to de...

journal_title：Human vaccines & immunotherapeutics

authors： Carman KB,Calik M,Karal Y,Isikay S,Kocak O,Ozcelik A,Yazar AS,Nuhoglu C,Sag C,Kilic O,Dinleyici M,Lacinel Gurlevik S,Yimenicioglu S,Ekici A,Perk P,Tosun A,Isik I,Yarar C,Arslantas D,Dinleyici EC

更新日期：2019-01-01 00:00:00

abstract：:Since the introduction of DNA vaccines two decades ago, this attractive strategy has been hampered by its low immunogenicity in humans. Studies conducted to improve the immunogenicity of DNA vaccines have shown that understanding the mechanism of action of DNA vaccines might be the key to successfully improving their ...

journal_title：Human vaccines & immunotherapeutics

authors： Coban C,Kobiyama K,Jounai N,Tozuka M,Ishii KJ

更新日期：2013-10-01 00:00:00

abstract：:Haemophilus influenzae type b (Hib) and 7-valent pneumococcal (PCV7) vaccines both became recommended in Japan in 2010. In this study, cytokine production was investigated in peripheral blood mononuclear cells (PBMCs) cultures stimulated with diphtheria and tetanus toxoids combined with acellular pertussis vaccine (DP...

journal_title：Human vaccines & immunotherapeutics

authors： Kashiwagi Y,Miyata A,Kumagai T,Maehara K,Suzuki E,Nagai T,Ozaki T,Nishimura N,Okada K,Kawashima H,Nakayama T

更新日期：2014-01-01 00:00:00

abstract：:HIV-infected patients are 30- to 100-fold more susceptible to invasive pneumococcal diseases than are healthy adults. Pneumococcal vaccination may be the best way to decrease the large pneumococcal disease burden, but the optimal timing of vaccination is still unclear. In this study, HIV-infected subjects aged ≥18 yea...

journal_title：Human vaccines & immunotherapeutics

authors： Song JY,Cheong HJ,Noh JY,Choi MJ,Yoon JG,Kim WJ

更新日期：2020-01-01 00:00:00

abstract：:The immune system becomes less effective with age, and older age is associated with an increased susceptibility to diseases and reduced responses to vaccination. Furthermore, some adult populations, such as those with diabetes mellitus, are at increased risk of acute hepatitis B virus (HBV) infection. Decreasing respo...

journal_title：Human vaccines & immunotherapeutics

authors： Van Der Meeren O,Crasta P,Cheuvart B,De Ridder M

更新日期：2015-01-01 00:00:00

abstract：:Tuberculosis (TB) is a significant cause of illness and death worldwide. Immunotherapy has been investigated in the treatment of TB. The purpose of this study was to perform a meta-analysis investigating the effectiveness of the M. vaccae vaccine. Medline, Cochrane, EMBASE, and Google Scholar were searched until Novem...

journal_title：Human vaccines & immunotherapeutics

authors： Huang CY,Hsieh WY

更新日期：2017-09-02 00:00:00

abstract：:In tick-borne encephalitis (TBE)-endemic regions, long-term vaccination programs are efficient in preventing the disease. A booster dose of a polygeline-free inactivated TBE vaccine (Encepur Adults, GSK), administered approximately 3 years post-primary vaccination according to 1 of 3 licensed vaccination schedules in ...

journal_title：Human vaccines & immunotherapeutics

authors： Costantini M,Callegaro A,Beran J,Berlaimont V,Galgani I

更新日期：2020-09-01 00:00:00

abstract：:In Chronic Myeloid Leukemia (CML), standard treatment consists of modern tyrosine-kinase inhibitors (TKI). Nevertheless, there is evidence that immune responses against leukemia-associated antigens (LAA) may play an important role in disease control. Dendritic cell (DC)- based immunotherapy is able to induce T cell re...

journal_title：Human vaccines & immunotherapeutics

authors： Flörcken A,Kopp J,Kölsch U,Meisel C,Dörken B,Pezzutto A,Westermann J

更新日期：2016-05-03 00:00:00

abstract：:Following the introduction of universal immunization against rotavirus, concerns were raised regarding pathogen-replacement of rotavirus by norovirus. The study aim was to examine the incidence and characteristics and norovirus gastroenteritis before and after the introduction of universal rotavirus immunization in Is...

journal_title：Human vaccines & immunotherapeutics

authors： Muhsen K,Kassem E,Rubenstein U,Goren S,Ephros M,Shulman LM,Cohen D

更新日期：2019-01-01 00:00:00

abstract：:The durable long term clinical benefits seen for certain patients treated with immunotherapy agents has suggested there is significant therapeutic potential to be derived from these agents, as shown by the increasing prominence of this treatment strategy in upcoming clinical trials. There has been a renewed interest a...

journal_title：Human vaccines & immunotherapeutics

authors： O'Sullivan Coyne G,Gulley JL

更新日期：2014-01-01 00:00:00

abstract：:The introduction of a serogroup A meningococcal conjugate vaccine in the African meningitis belt has been a remarkable success. Meningitis due to the serogroup A meningococcus, previously responsible for most epidemics, has fallen by 99% in vaccinated countries. Success must, however, not distract from the continuing ...

journal_title：Human vaccines & immunotherapeutics

authors： Stuart JM

更新日期：2018-05-04 00:00:00

abstract：:Maternal vaccination offers the opportunity to protect pregnant women and their infants against potentially serious disease. As both pregnant women and their newborns are vulnerable to severe illness, the potential public health impact of mass maternal vaccination programs is remarkable. Several high-income countries ...

journal_title：Human vaccines & immunotherapeutics

authors： Regan AK

更新日期：2016-12-01 00:00:00

abstract：:Influenza vaccination is the cornerstone of prophylaxis. The regulatory authorities currently annually license vaccines based on serum antibodies directed toward the major surface glycoprotein haemagglutinin (HA). The most commonly used serological test, the haemagglutination inhibition (HI) assay utilizes red blood c...

journal_title：Human vaccines & immunotherapeutics

authors： Cox RJ

更新日期：2013-02-01 00:00:00

abstract：:Introduction: The aim of this study was to determine the knowledge, attitudes, and practices of family physicians and pediatricians in regard to adolescent immunization.Methods: The study was conducted from March to May 2017. A total of 665 physicians participated. Participants were asked 31 questions about their pers...

journal_title：Human vaccines & immunotherapeutics

authors： Kara Elitok G,Bulbul L,Altuntas SB,Altuntas B,Günindi G,Haltaş M,Yuvarlan A,Toprak D,Bulbul A

更新日期：2020-05-03 00:00:00

abstract：:Influenza may cause severe complications for pregnant women. In this study antibody response against 2009 H1N1 influenza virus in pregnant women was investigated. This seroprevalance cross sectional and questionnaire based study was conducted using a convenient sampling method. Blood samples of pregnant women were che...

journal_title：Human vaccines & immunotherapeutics

authors： Honarvar B,Moghadami M,Moattari A,Emami A,Tabatabaee HR,Jahromi BN,Asadi N,Mousavizadeh A,Lankarani KB,Joulaei H,Ghaffarpasand F

更新日期：2012-05-01 00:00:00

abstract：:The immune system responds to tumor cells. The challenge has been how to effectively use these responses to treat or protect against cancer. Toward the goal of developing a cancer vaccine, we are pursuing methodologies for the discovery and testing of useful antigens. We present an array-based approach for discovering...

journal_title：Human vaccines & immunotherapeutics

authors： Whittemore K,Sykes K

更新日期：2013-10-01 00:00:00

abstract：:We report the findings of three randomized, double-blind, placebo-controlled Phase I studies undertaken to support licensure of the liquid formulation of the human G1P[8] rotavirus (RV) vaccine (RIX4414; GlaxoSmithKline Biologicals SA) in China. Healthy adults aged 18-45 y (n=48) and children aged 2-6 y (n=50) receive...

journal_title：Human vaccines & immunotherapeutics

authors： Li RC,Li YP,Mo ZJ,Luo D,Huang T,Kong JL,Wang LH,Song NS,Liu A,Zhang H,Liao X,Karkada N,Han HH

更新日期：2013-08-01 00:00:00

abstract：:HIV sequence diversity and the propensity of eliciting immunodominant responses targeting inessential variable regions are hurdles in the development of an effective AIDS vaccine. We developed a DNA vaccine comprising conserved elements (CE) of SIV p27Gag and HIV-1 Env and found that priming vaccination with CE DNA is...

journal_title：Human vaccines & immunotherapeutics

authors： Hu X,Lu Z,Valentin A,Rosati M,Broderick KE,Sardesai NY,Marx PA,Mullins JI,Pavlakis GN,Felber BK

更新日期：2018-01-01 00:00:00

abstract：:This review aims to present the unique considerations for manufacturing and the regulation of new vaccines in Muslim-populated countries such as Malaysia. Our specific objectives are to highlight vaccine production and the ingredients of concern, summarize the current mechanism for ruling and recommendations on new va...

journal_title：Human vaccines & immunotherapeutics

authors： Khoo YSK,Ghani AA,Navamukundan AA,Jahis R,Gamil A

更新日期：2020-03-03 00:00:00

abstract：:While most pathogens infect via mucosal surfaces, most current vaccines are delivered by injection. This situation remains despite awareness of the potential benefits of mucosal delivery for inducing protection against mucosa-infecting pathogens. A major obstacle to the development of such vaccines is the paucity of s...

journal_title：Human vaccines & immunotherapeutics

authors： Timothy AA,Tokanovic A,Snibson KJ,Edwards SJ,Pearse MJ,Scheerlinck JP,Sutton P

更新日期：2015-01-01 00:00:00

abstract：:The multicomponent meningococcal serogroup B vaccine, 4CMenB, has demonstrated effectiveness in preventing invasive MenB disease in infants and in controlling MenB outbreaks. The need for/timing of additional booster doses is not yet established. We reviewed eight studies that evaluated antibody persistence and booste...

journal_title：Human vaccines & immunotherapeutics

authors： Martinón-Torres F,Nolan T,Toneatto D,Banzhoff A

更新日期：2019-01-01 00:00:00

abstract：:Background: Rotavirus (RV) is worldwide an important cause of acute gastroenteritis (AGE) in infants and young children. There is no specific treatment for AGE caused by RV (RVGE) but since 2006 two safe and effective vaccines have been available. RV vaccination was included in the national immunization program (NIP) ...

journal_title：Human vaccines & immunotherapeutics

authors： Tafalla M,Gardovska D,Gopala K,Kozlovska L

更新日期：2019-01-01 00:00:00

abstract：:Vaginal and vulvar cancers do not account for a large proportion of gynecologic malignancies but their impact is significant. Both vaginal and vulvar lesions have precursors and display levels of dysplasia before progression to invasive disease. Human Papillomavirus (HPV) is a known causative agent of such dysplasia a...

journal_title：Human vaccines & immunotherapeutics

authors： Buchanan TR,Graybill WS,Pierce JY

更新日期：2016-06-02 00:00:00

abstract：:In recent years, nanomedicine has transformed many areas of traditional medicine, and enabled fresh insights into the prevention of previously difficult to treat diseases. An example of the transformative power of nanomedicine is a recent nano-vaccine against listeriosis, a serious bacterial infection affecting not on...

journal_title：Human vaccines & immunotherapeutics

authors： Calderon-Gonzalez R,Marradi M,Garcia I,Petrovsky N,Alvarez-Dominguez C

更新日期：2015-01-01 00:00:00

abstract：:Hepatitis A is a vaccine-preventable infection caused by the HA virus (HAV) with transitional to intermediate endemicity in China. An inactivated vaccine first licensed in China in 2010 (Avaxim® 80U Pediatric) is indicated for primary and booster vaccination in children from 12 months to 15 years of age. This Phase IV...

journal_title：Human vaccines & immunotherapeutics

authors： Shi N,Rasuli A,Thollot Y

更新日期：2019-01-01 00:00:00

abstract：:The development of a successful vaccine, which should elicit a combination of humoral and cellular responses to control or prevent infections, is the first step in protecting against infectious diseases. A vaccine may protect against bacterial, fungal, parasitic, or viral infections in animal models, but to be effecti...

journal_title：Human vaccines & immunotherapeutics

authors： Zheng Z,Diaz-Arévalo D,Guan H,Zeng M

更新日期：2018-07-03 00:00:00

abstract：:The programmed cell death protein 1 (PD1) is one of the checkpoints that regulates the immune response. Ligation of PD1 with its ligands PDL1 and PDL2 results in transduction of negative signals to T-cells. PD1 expression is an important mechanism contributing to the exhausted effector T-cell phenotype. The expression...

journal_title：Human vaccines & immunotherapeutics

authors： Kwok G,Yau TC,Chiu JW,Tse E,Kwong YL

更新日期：2016-11-01 00:00:00

abstract：:The Maternal Neonatal Tetanus Elimination program is proof of concept for the feasibility and potential for maternal immunization to reduce neonatal mortality particularly in low and middle-income countries. Introduction of any additional vaccine into the antenatal space, such as Influenza and Pertussis, and potential...

journal_title：Human vaccines & immunotherapeutics

authors： Krishnaswamy S,Lambach P,Giles ML

更新日期：2019-01-01 00:00:00

abstract：:Rotavirus (RV) and norovirus (NoV) are the 2 leading causes of acute viral gastroenteritis worldwide. We have developed a non-live NoV and RV vaccine candidate consisting of NoV virus-like particles (VLPs) and recombinant polymeric RV VP6 protein produced in baculovirus-insect cell expression system. Both components h...

journal_title：Human vaccines & immunotherapeutics

authors： Blazevic V,Malm M,Arinobu D,Lappalainen S,Vesikari T

更新日期：2016-03-03 00:00:00